ACOR - Acorda Therapeutics Stock Trading

$80 million up-front payment will substantially increase cash balance Sale, restructuring and other operating expense reductions will reduce annual operating expenses by approximately $40 million Total 2021 non-GAAP operating expense guidance expected to be $130-$140 million ...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Health Care Conference on Thursday, January 14, at 5:20 PM ET. A live audio webcast of the presentation can be accessed under ...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11 th -14 th H.C. Wainwright BIOCONNECT Virtual Conference. An audio webcast of the presentation can be accessed under “Investor...